Wednesday, August 26, 2015 10:13:43 PM
I appreciate your candor. Perhaps I can change your "big veto" to a small "maybe, it's possible". I'll try to make a case for it.
Please view the section I referenced from the most recent 10K, released in April 2015. When I read that particular section, my impression is that the Company alludes to a sincere interest in obtaining the entire GBM market. Upon that, they'll go after less grade cancers; though, not before, after. It makes sense to me to consider doing so now, and get that young age cohort in their GBM Orphan designation (7 and 10 year marketing exclusivity). They did temporarily suspend screening for something, and it may very well be that their temporary halt is somehow related to screening. Can't see why recruiting a young age would be so far fetched. I personally can't rule screening is permanently halted until the Company confirms it so. Can you?
As for treating children with GBM with immunotherapy, Annias is already doing it. As such I do not expect to see any road-block from regulators with regards to treating children with DCVax-L. Earlier this month, the National Cancer Institute awarded Annias Immunotherapeutics, Inc with a $1,227,385 grant to fund its peptide vaccine research (pasted below, with relevant/interesting sections highlighted). In my view, NW Bio should be thinking about this children market quite seriously, and soon.
Recent NWBO News
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/10/2024 09:04:57 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/01/2024 10:04:38 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/02/2023 01:31:35 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/16/2023 10:11:54 PM
- Epazz, Inc. (OTC Pink: EPAZ) ZenaDrone Demonstration to Defense Departments of UAE and Saudi Arabia • InvestorsHub NewsWire • 11/15/2023 12:19:31 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/09/2023 09:30:39 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 • InvestorsHub NewsWire • 11/09/2023 01:00:34 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 Extreme Weather Demo • InvestorsHub NewsWire • 11/07/2023 12:29:43 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/09/2023 08:36:14 PM
Avant Technologies Equipping AI-Managed Data Center with High Performance Computing Systems • AVAI • May 10, 2024 8:00 AM
VAYK Discloses Strategic Conversation on Potential Acquisition of $4 Million Home Service Business • VAYK • May 9, 2024 9:00 AM
Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM
Element79 Gold Corp Successfully Closes Maverick Springs Option Agreement • ELEM • May 8, 2024 9:05 AM
Kona Gold Beverages, Inc. Achieves April Revenues Exceeding $586,000 • KGKG • May 8, 2024 8:30 AM
Epazz plans to spin off Galaxy Batteries Inc. • EPAZ • May 8, 2024 7:05 AM